A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

508

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Refractory Multiple Myeloma

Interventions

BIOLOGICAL: AZD0120
DRUG: Daratumumab
DRUG: Carfilzomib
DRUG: Dexamethasone
DRUG: Bortezomib
DRUG: Pomalidomide

Sponsor

AstraZeneca